Editorial: Advances in the treatment of chronic myeloid leukemia.
作者信息
Eşkazan Ahmet Emre, Kok Chung H, Yeung David, Dalal Jignesh, Tiribelli Mario
机构信息
Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia.
出版信息
Front Oncol. 2023 Mar 9;13:1166588. doi: 10.3389/fonc.2023.1166588. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Advances in the treatment of chronic myeloid leukemia.社论：慢性髓性白血病治疗进展
Front Oncol. 2023 Mar 9;13:1166588. doi: 10.3389/fonc.2023.1166588. eCollection 2023.
2
Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.早期BCR-ABL1降低可预测接受任何酪氨酸激酶抑制剂治疗的新诊断慢性髓性白血病患者无事件生存期更佳。
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1.
3
The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.BCR-ABL1 转录本类型对慢性髓性白血病患者酪氨酸激酶抑制剂反应和结局的影响。
Cancer. 2018 Oct 1;124(19):3806-3818. doi: 10.1002/cncr.31408. Epub 2018 Apr 25.
4
BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors.BCR-ABL1 转录本水平在 4 周时对特定时间的反应和预测接受各种酪氨酸激酶抑制剂治疗的慢性期慢性髓性白血病患者的生存具有预后意义。
Cancer Med. 2018 Oct;7(10):5107-5117. doi: 10.1002/cam4.1753. Epub 2018 Aug 31.
5
[Practical management of side effects of tyrosine kinase inhibitor therapy in chronic myeloid leukemia].[慢性髓性白血病酪氨酸激酶抑制剂治疗副作用的实际管理]
Orv Hetil. 2021 Jul 25;162(30):1198-1207. doi: 10.1556/650.2021.32177.
6
BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.BCR-ABL1 转录本在 3 个月时可预测伊马替尼治疗失败的慢性期慢性髓性白血病患者接受第二代酪氨酸激酶抑制剂治疗后的长期结局。
Br J Haematol. 2013 Mar;160(5):630-9. doi: 10.1111/bjh.12187. Epub 2012 Dec 24.
7
Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.慢性髓性白血病患者中一种新型BCR-ABL1融合转录本的特征分析：对分子监测的意义
Hematol Oncol Stem Cell Ther. 2017 Jun;10(2):85-88. doi: 10.1016/j.hemonc.2016.02.002. Epub 2016 Mar 17.
8
Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts.伴有罕见 BCR-ABL1 转录本的慢性髓性白血病的临床特征和预后意义。
Leuk Lymphoma. 2019 Dec;60(12):3051-3057. doi: 10.1080/10428194.2019.1607329. Epub 2019 Jul 1.
9
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.伊马替尼一线治疗慢性髓性白血病慢性期患者 BCR-ABL1 转录本第二次下降率对临床结局的影响。
Ann Hematol. 2019 May;98(5):1159-1168. doi: 10.1007/s00277-019-03633-x. Epub 2019 Feb 23.
10
BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.用于治疗慢性粒细胞白血病的BCR-ABL1酪氨酸激酶抑制剂
J Oncol Pharm Pract. 2018 Sep;24(6):433-452. doi: 10.1177/1078155217710553. Epub 2017 Jun 4.
引用本文的文献
1
The PD1 Molecule May Contribute to Lower Treatment-Free Remission Rates in Patients with Chronic Myeloid Leukemia with the e13a2 Transcript.PD1分子可能导致携带e13a2转录本的慢性髓性白血病患者的无治疗缓解率较低。
J Clin Med. 2025 Mar 27;14(7):2304. doi: 10.3390/jcm14072304.
本文引用的文献
1
First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.一线伊马替尼与第二代和第三代酪氨酸激酶抑制剂用于慢性期慢性粒细胞白血病的疗效比较：一项系统评价和荟萃分析。
Blood Adv. 2020 Jun 23;4(12):2723-2735. doi: 10.1182/bloodadvances.2019001329.
2
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey.意大利新冠疫情期间慢性髓系白血病的管理。一项校园慢性髓系白血病调查。
Leukemia. 2020 Aug;34(8):2260-2261. doi: 10.1038/s41375-020-0904-z. Epub 2020 Jun 18.
3
The impact of BCR-ABL1 transcript type on tyrosine kinase inhibitor responses and outcomes in patients with chronic myeloid leukemia.BCR-ABL1 转录本类型对慢性髓性白血病患者酪氨酸激酶抑制剂反应和结局的影响。
Cancer. 2018 Oct 1;124(19):3806-3818. doi: 10.1002/cncr.31408. Epub 2018 Apr 25.
Zotero 插件